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ABSTRACT 
Cystic fibrosis (CF) patients battle life-long pulmonary infections with the respiratory pathogen 
Pseudomonas aeruginosa (PA). A favorable niche for PA growth is provided by an 
overabundance of mucus in CF airways. When compared to that of non-CF individuals, mucus of 
CF airways has been found to be enriched in sialic acid, especially in the form of the tetra 
carbohydrate moiety sialyl-Lewisx, which is a preferred binding receptor for PA. Furthermore, 
sialyl-Lewisx levels have previously been shown to directly correlate with infection levels in CF 
patients. In this study, we examined the ability of PA virulence factors pyocyanin (PCN), LPS, 
flagella and alginate to modulate the levels of sialyl-Lewisx modifications on airway mucins in a 
mouse model and in in vitro cell culture.  We found PCN to be a potent inducer of sialyl-Lewisx 
in both mouse airways and in the cultured airway epithelial cells. PCN increases the expression 
of ST3Gal-IV and C2/4GnT, two enzymes responsible for the stepwise synthesis of sialyl-Lewisx 
through a TNF-α dependent phosphoinositol-specific phospholipase C (PI-PLC) pathway. 
Importantly, PA is better able to bind airway epithelial cells previously exposed to PCN. These 
results suggest that PA secretes PCN to induce a favorable environment for chronic colonization 
of CF lungs by increasing the glycosylation of airway mucins with sialyl-Lewisx. 
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INTRODUCTION 
 
 
Pulmonary bacterial infections with Pseudomonas aeruginosa (PA) are a critical clinical 
concern for patients living with cystic fibrosis (CF) (Boucher, 2002; Lyczak et al., 2002), 
underscored by the finding that 97% of CF patients are colonized with PA by age three (Burns et 
al., 2001). Pulmonary failure, as a sequela of acute exacerbations and tissue scarring in chronic 
infections, results in a large majority of mortality in CF patients (Boucher, 2002; Lyczak et al., 
2002). Previously understood contributing factors to PA pathogenesis in the CF lung involve 
overproduction of hyperviscous mucus and impeded mucocilliary clearance of trapped bacteria 
in airways (Boucher, 2002).  The ability of PA to initially and persistently colonize the lung is an 
important factor in determining the course and chronicity of infection (Carnoy et al., 1994; 
Lamblin et al., 2001).  
Airway mucus is comprised of mucin glycoproteins and water. The structure of mucin 
glycoproteins contains a diverse population of carbohydrate chains that have been shown to be 
receptors for bacteria, and whose intraluminal location in the airway serves as a first line of 
interaction with microbes in the lung (Colomb et al., 2012; Scharfman et al., 1999; Delmotte et 
al., 2002; Lamblin et al., 2001). Mucins recovered from the lungs of CF patients have been 
shown to be enriched with the tetra carbohydrate structure sialyl-Lewisx (Lo-Guidice et al., 
1994; Lamblin et al., 1984; Davril et al., 1999). Several studies have independently shown that 
PA binds these modified CF mucins with a higher affinity over control tissues and other 
carbohydrate moieties, respectively (Carnoy et al., 1993; Carnoy et al., 1994; Devaraj et al., 
1994, Scharfman et al., 1999). It has been thoroughly established that the enzymes core 2 β1, 6 
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N-acetylglucosaminlytransferase (C2/4GnT) and α2, 3-sialyltransferase IV (ST3Gal-IV) are crucial 
for sialyl-Lewisx synthesis, and are upregulated in conditions of pulmonary inflammation, which 
is a characteristic typical of the CF lung (Delmotte et al., 2001; Delmotte et al., 2002; Groux-
Degroote et al., 2008; Ishibashi et al., 2005; Colomb et al., 2012). Specifically, levels of sialyl-
Lewisx increase in response to treatment with TNF-α, IL-6 and IL-8.  However, although the CF 
epithelium has been shown to be hyper reactive and to have a prolonged inflammatory 
response to stimuli when compared to tissue from non-CF patients (Muhlebach & Noah, 2002), 
several reports have shown that inflammation cannot initially occur in the absence of bacteria 
(Berger, 2002; Dakin et al., 2002; Muhlebach & Noah, 2002). Therefore, increases in sialyl-
Lewisx cannot be exclusively attributed to tissue differences due to primary diseases. The 
further finding of a direct correlation between severity of infection and the levels of sialyl-
Lewisx on bronchial mucins (Davril et al., 1999) underscores the importance of a bacterial 
etiology as an initial inciting factor in the modification of these mucins. Together, these findings 
warrant investigation in order to facilitate a deeper understanding of the effects of PA in 
relation to these changes in sialyl-Lewisx levels. 
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LITERATURE REVIEW 
 
 
Cystic fibrosis history and incidence 
 
Cystic fibrosis is the most common life-limiting genetic disease among people of Caucasian 
heritage (O’Sullivan & Freedman, 2009). Cystic fibrosis became classified as an independent 
disease in 1938, at which time it was distinguished from a general disorder of malabsorption, 
known as celiac’s disease (Andersen, 1938). This distinction was prompted by the finding of 
lesions in the pancreatic ducts on autopsy of a portion of infants who died from 
malnourishment, and prompted the condition to be termed “cystic fibrosis of the pancreas” 
(Andersen, 1938). Because many exocrine glands were found to be affected (di Sant Anese, 
1956), and the observation of an autosomal recessive inheritance pattern was found (Andersen 
& Hodges, 1946), a fervent research effort began to search for a genetic origin of this disease. 
Because of the abnormally thick mucus that often was found to block airways, the initial search 
was focused on the mucus as the source of the defect (Davis, 2007). This changed in 1948, 
during a heat wave in New York, when a pediatrician noticed that the majority of the infants 
being presented to him for heat-related symptoms had CF (di Sant’ Agnese et al., 1953). He 
hypothesized that they were unable to tolerate the heat due to decreased cooling by sweating, 
and examined their sweat for abnormalities. He found that the Na and chloride present in the 
sweat of these patients was fivefold higher than normal. This led to investigation of the Na 
chloride channels for clues about the disease, and to a better way to test for CF disease, one 
that is still used today- the “sweat test” (Quinton et al., 2012).  The elevated Na and chloride in 
sweat is found in almost all individuals with CF, and almost none without it. This test also allows 
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for the identification of patients with milder symptoms, who may not have signs of pancreatic 
disease as seen with more severe cases of CF (Quinton et al., 2012; Davis, 2007).  It was not 
until 1983 that chloride transport was found to be the basic defect in the disease (Quinton, 
1983). Shortly after, the CF gene was discovered in 1989 (Kerem et al., 1989; Riordan et al., 
1989; Rommens et al., 1989). Currently, “cystic fibrosis” is used to describe patients with a 
mutation in this gene, which is expressed in many types of epithelial cells. These cells are found 
in many organs, including the sweat ducts, airways, pancreatic ducts, intestine and biliary tree. 
The phenotype of this disease is one that will eventually develop into progressive, fatal lung 
disease (Davis, 2007).   
 
The incidence of cystic fibrosis is highest in European- derived populations, with 1 in 
2000-3000 births affected (Farrell, 2000), and a carrier rate of 1 in 26 (Romeo et al., 1989). The 
incidence in North America is lower, with approximately 1 in 3,500 births affected (Kosorok et 
al., 1996). The outlook for patients with CF today is much more promising than in the past. A 
model used in the United Kingdom predicts median survival ages of >50 years old for children 
born after the year 2000 (Dodge et al., 2007). 
 
 Pathology of CF: primary genetic defect 
 
The cystic fibrosis gene, termed the cystic fibrosis transmembrane conductance 
regulator (CFTR), was identified on the long arm of human chromosome 7 in 1989 (Rommens et 
al., 1989; Kerem et al., 1989; Riordan et al., 1989). There are over 1,000 different recorded 
mutations in the CFTR gene to date (Cystic Fibrosis Gene Consortium). Mutations in this gene 
result in multi organ disease affecting populations of epithelial cells throughout the body 
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(Boucher, 2002). These effects translate to a variety of disease manifestations which reflect the 
many functions of the CFTR protein, and the range of possible phenotypes resulting from the 
CFTR defect. (Tsui, 1995).  The vast majority (70%) of CFTR mutations are caused by a deletion 
of three base pairs that code for a phenylalanine at position 508, which is noted as ∆F508 CFTR 
(Cystic Fibrosis Gene Consortium). This mutation confers abnormal folding in the CFTR protein 
during translation, which leads to recognition and labeling by chaperone proteins that direct 
the degradation of the CFTR protein prior to its transit to the apical plasma membrane. (Cheng 
et al., 1990; Ward et al., 1995).  
 
 The CFTR channel has been shown to be vital in the regulation of airway surface liquid 
(ASL) volume (Matsui et al., 1998). The ASL is composed of two layers, the first being a thin 
(7µm), low density, pericilliary liquid (PCL), that surrounds the airway cilia, and provides a low-
viscosity medium in which they can beat (Tarran et al., 2001a). The second is a layer of mucus 
that sits on top of the PCL layer, which traps debris and pathogens, and is constantly being 
moved proximally via the beating action of the cilia to remove trapped foreign objects from the 
airway (Tarran et al., 2001a; Tarran et al.; 2001b).  
 
In normal individuals, the CFTR functions as a cAMP-mediated chloride channel, serving 
in electrolyte homeostasis at the luminal surface of the airway. Specifically, the CFTR can 
secrete chloride ions (Bear et al., 1992; Rich et al., 1990), which establish an osmotic gradient 
favorable for addition of water to the ASL (Boucher, 1994a; Boucher, 1994b, Boucher, 2002) 
The CFTR channel also provides tonic inhibition of the epithelial sodium channel (ENaC) (Stutts 
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et al., 1995), a sodium channel also found on the apical surface of airway epithelium. With the 
loss of CFTR in CF, the tonic inhibition on the ENaC is lost, leading to an unregulated increase in 
the absorption of sodium ions into the cell. To balance out the charge, chloride ions are 
absorbed through the paracellular pathway (Boucher, 1994a; Boucher, 1994b), leading to a net 
increase in absorption of sodium chloride (NaCl) into the epithelium (Jiang et al., 1993; Matsui 
et al., 1998; Tarran et al., 2001b). The resulting osmotic gradient favors the increased 
absorption of water, which depletes the PCL, slows mucus clearance from the lung, and 
eventually causes mucus to directly contact and adhere to the surface of the cilia (Matsui et al., 
1998). The mucus layer can act as a reservoir to donate water to the PCL in order to 
compensate for the volume depletion (Tarran et al., 2001a), although this changes it’s physical 
characteristics to be more viscous and concentrated (Boucher, 2002). With a non-functional 
CFTR, chloride ion release to reverse this gradient and add water back to the ASL is not possible 
(Knowles et al., 1983).   In addition, there is evidence that the mucus-producing mechanism of 
goblet cells has a very poor feedback mechanism, as there is continued production in the face 
of reduced clearance. This results in increased mucus layer depth, and leads to mucus plugging 
and bronchiectasis (Boucher, 2002). It is this mechanism of the CFTR’s effect on ASL volume 
that is commonly agreed upon to be the link between the genetic mutation and the chronic 
lung disease that is characteristic of CF (Matsui et al. 1998; Tarran et al., 2001a). 
 
Pathology of CF: secondary bacterial infections  
 
The primary defects in mucocilliary clearance discussed earlier prime the CF lung for 
bacterial infection. Analysis has shown that bacterial defensins in the mucus layer are capable 
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of controlling  bacterial growth and even decreasing CFU for up to 6hrs (Cole et al., 1999), 
which is the normal amount of time for mucocilliary clearance in a non-CF airway (Wanner et 
al., 1996).  After this, the bacteria were able to overcome the defensins, and flourish into 
productive infections in the airway (Cole et al., 1999), confirming the importance of the speed 
of mucus transport in the airway. Chronic cycles of bacterial infection with periods of acute 
exacerbation are considered the most challenging clinical feature of CF lung disease, and one 
that results in the death of 80-95% of CF patients (Lyczak et al., 2002).  These infections are 
commonly caused by opportunistic infections of normal flora of the respiratory tract (H. 
influenza, S. aureus), or common non-pathogenic environmental pathogens (P. aeruginosa). 
Bacterial infections with H. influenza and S. aureus are more prevalent early in the life of CF 
patients, but decline drastically with time (Strausbaugh & Davis, 2007; Lyczak, 2002).  Infections 
with the gram negative Pseudomonas aeruginosa (PA) are by far the most common, and 
incidence dramatically increases with age (Lyczak, 2002; Strausbaugh & Davis, 2007).  
 
Pseudomonas aeruginosa has been shown to thrive and form biofilms in the hypoxic 
conditions of mucus plaques in CF airways (Worlitzsch et al., 2002), and in this way is well 
adapted for infection in the CF lung. Growth in biofilms and within mucus also provides PA with 
increased resistance to antimicrobial therapies (Drenkard, 2003). Resistance to antimicrobial 
agents by PA is also acquired through the ability of the pathogen to rapidly develop adaptation 
strategies to numerous classes of antimicrobials (Tseng et al., 1972; Bryan et al., 1972b). One of 
the most concerning clinical problems associated with PA infection is a large inflammatory 
response (Lyczak, 2002), which can progressively damage airways and lead to declined 
pulmonary function, and eventually, failure (Boucher, 2002; Emerson et al., 2002).  Although CF 
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epithelium has been shown to have an exaggerated and prolonged inflammatory response as 
compared to non-CF tissue (Muhlebach & Noah, 2002; DiMango et al., 1995), other studies 
have shown that inflammation does not occur without an initial inciting bacterial stimulus 
(Burns, 2001). The inflammatory reaction, characterized by increased neutrophil count and IL-8 
levels, has been shown to begin in young patients (<6mo.), even though infection levels are low 
(Khan et al., 1995).  
Patients with CF, after chronic colonization with PA, experience acute exacerbations 
with inflammation that require aggressive antibiotic therapy for control.  Neutrophillic 
infiltration is the dominant inflammatory response in CF airways (Konstan et al., 1994), and it is 
the neutrophils themselves which have been shown to perpetuate the inflammation and 
subsequent lung damage of CF (Khan et al., 1995). This damage is caused by neutrophil release 
of damaging oxidants (Van Der Vliet et al., 2000), and proteases. One of the most damaging 
proteases is elastase, which has been shown to degrade nearly all the structural proteins of the 
lung including elastin, collagen type IV, fibronectin and proteoglycan (Janoff et al., 1979), 
contributing to parenchymal destruction and airway remodeling.  The PA bacteria can also 
contribute to airway pathology through the effects of several secreted and non- secreted 
factors on airway epithelia. (Caldwell et al., 2009; Lau et al., 2005). Pyocyanin (PCN), a redox 
active phenazine toxin secreted from stationary phase PA, is found in CF airways in 
concentrations of 100uM (27ug/mL) (Wilson et al. 1988). PCN has been shown to be critical for 
PA infection in mouse airways (Lau et al., 2004). Prolonged administration of purified PCN into 
mouse airways has been shown to cause goblet cell hyperplasia and metaplasia, airway fibrosis 
and alveolar airspace destruction, consistent with pathology found in chronically infected CF 
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airways (Caldwell et al., 2009). Pyocyanin can freely cross cell membranes and exert an 
oxidative effect on cytosolic and mitochondrial components, inducing oxidative stress and 
interfering with airway epithelial cell metabolism (Rada & Leto, 2009). Pyocyanin also induces 
apoptosis in neutrophils, causing them to release oxidative granzyme material, further 
damaging epithelial cell tissues (Usher et al., 2002).  These mechanisms demonstrate PA’s 
ability to cause inflammation and tissue injury in the lung, leading to the phenotypic 
characteristics of serious progressive lung disease in cystic fibrosis.  
 
Mucin glycoproteins: structure and modifications in CF 
Airway mucus is composed of water (97%) and high molecular weight glycoproteins 
called mucins (2%) (Fahy & Dickey, 2010). Mucins are synthesized in goblet cells and 
submucosal glands in the conducting airways (trachea, bronchi, and bronchioles) of the 
respiratory tree, and can either be secreted or membrane-tethered (Rose & Voynow, 2006; 
Fahy & Dickey, 2010).  Mucin glycoprotein synthesis involves transcription in the nucleus of one 
of the 17 MUC genes in the human genome to encode a MUC mRNA, which is translated to a 
mucin protein backbone on ribosomes in the endoplasmic reticulum, and then post-
translationally modified by the addition of O-glycosylations in the cis-golgi (Rose & Voynow, 
2006; Thornton et al, 2008, Rose, 1992).  Two of the most abundant mucins found in human 
airways are the secreted, polymer-forming MUC5AC and MUC5B. (Rose & Voynow, 2006; 
Thornton et al., 2008). Post translational modification leaves mucin glycoproteins heavily 
glycosylated, with carbohydrate side chains representing 50-90% of their total weight (Rose & 
Voynow, 2006). These side chains can bind liquids to increase the weight of the mucin several 
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hundred times. These well-hydrated mucins allow the mucus layer to serve as a lubricant for 
the mucous membrane as well as a liquid reservoir for the PCL that is located beneath it 
(Knowles & Boucher 2002, Rose, 1992). The structure of the MUC protein backbone includes an 
NH2 terminal domain, a central region with regions of tandem repeats (TR) separated by 
cysteine-rich regions, and a COOH terminal domain (Thornton et al., 2008; Rose & Voynow, 
2006; Rose, 1992). The TR structures are rich in serine and threonine, which are attachment 
sites for the O-glycans (Hang & Bertozzi, 2005; Rose 1992). Therefore, the more TR regions that 
a mucin has, the more heavily glycosylated it will ultimately be (Rose & Voynow, 2006). For 
example, MUC5B contains a TR sequence with 16 serine or threonine sites for possible O-glycan 
attachment. This TR sequence is repeated 72 times in the central region of the mucin backbone, 
affording over 1,100 possible attachment sites (Rose & Voynow, 2006). The glycosylation 
structure is comprised of a core, backbone and terminal region (Hanisch 2001). Four main core 
structures exist (Brockhausen et al., 1985), and all have a base N-acetylgalactosamine (GalNAc) 
in common, which is added onto a serine or threonine of the mucin peptide backbone through 
the action of N-acetylgalactosaminyl peptidase enzyme (Rose, 1992).  Once this initial addition 
is in place, combinations of single-chain or branched conformation galactose (Gal) and N-
acetylglucosamine (GlcNAc) are added by their respective glycosyltransferase enzymes to form 
one of the possible four main core conformations of the glycan (Rose, 1992, Brockhausen et al., 
1985). These core structures can be elongated by the addition of the repetitive disaccharide 
element Galβ1-4GlcNAc to the core, which forms the backbone portion of the glycosylation 
chain (Hansich, 2001). The terminal regions of the glycosylations are complex, due to the 
addition of many possible structures (Hanisch, 2001). Terminal structures can be modified with 
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additions of N-acetylneuraminic acid (sialic acid), fucose, sulfate, or blood group determinants 
(Hanish, 2001; Rose, 1992). These terminal additions can affect the rheological properties of the 
mucus. Specifically, N-acetylneuraminic acid and sulfate confer a negative charge to the mucin, 
and fucose has hydrophobic properties (Rose & Voynow, 2006).  
 
Terminal additions to mucins have been found to be altered in CF, with enrichment in 
sulfate and sialic acid (Lo-Guidice et al., 1994).  Enrichments in sulfate can be attributed to the 
CFTR primary genetic mutation, as CFTR-mediated increases in acidity within the cell increase 
the addition of sulfate to mucins (Zhang, 1995). Differences in sialic acid, however, cannot be 
easily linked to the CFTR mutation, and have rather been associated with increased 
inflammation in the CF lung with chronic infection (Lo-Guidice et al., 1994; Lamblin et al., 1984; 
Davril et al., 1999). The sialic acid, most often, is found in the form of the tetra carbohydrate 
structure sialyl-Lewisx (NeuAcα2-3Galβ1-4{Fucα1-3}GlcNAc-R).  Sialyl-Lewisx has been shown to 
be a preferential binding receptor for PA (Carnoy et al., 1993; Carnoy et al., 1994; Devaraj et al., 
1994; Scharfman et al., 1999). Sialyl-Lewisx, is formed in a stepwise fashion by many different 
glycosyl- and sialyltransferases (Delmotte et al., 2002b; Chen, 2011)   These enzymes have also 
been shown to  be upregulated in conditions of inflammation. (Groux-Degroote et al., 2008; 
Delmotte et al., 2001; Delmotte et al., 2002; Ishibashi et al., 2005)  Specifically, studies have 
shown increased levels of sialyl-Lewisx in response to inflammatory cytokines IL-8, IL-6 and TNF-
α.  In contrast to the regulation of mucin production, which has been shown to be modulated 
through the EGFR pathway (Hao et al., 2012; Ishibashi et al., 2005) regulation of TNF-α -
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dependent terminal addition of sialyl-Lewisx has been found to be controlled through the 
phosphoinositol-specific phospholipase C (PI-PLC) pathway (Ishibashi et al., 2005). 
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RESEARCH JUSTIFICATION 
 
 
Cystic fibrosis is the most common life-limiting genetic disorder in populations of 
European heritage. Although the life expectancy for patients with CF has increased dramatically 
over the last 30 years, much of the therapy relies on aggressive antibiotic treatment of chronic 
pulmonary infections. The most common etiologic agent of these infections is Pseudomonas 
aeruginosa (PA), which can evade and/or develop resistance to last line antibiotic therapy 
options. The result is uncontrolled fulminant pulmonary inflammation, which leads to airway 
and parenchymal tissue destruction in the lung, and a subsequent pulmonary functional decline 
and failure. This pattern of pathogenesis necessitates better understanding of the mechanisms 
of PA airway infection. Previous work has established a link between PA pulmonary infection 
levels and increased expression of the preferential binding receptor sialyl-Lewisx on airway 
mucins. Despite this, no work examining the effect of purified virulence factors on the 
expression of sialyl-Lewisx has been completed. The study herein describes the effect of several 
purified virulence factors on the expression of sialyl-Lewisx and its biosynthetic enzymes, and 
impact on PA binding efficiency to airway epithelial cells. A deeper understanding of the 
mechanisms of PA colonization and infection in the lung will afford new possibilities for 
treatment targets or further research with the aim to improve the outcome of chronic PA lung 
infection in CF patients.  
 
 
 
 
14 
 
RESULTS 
 
Pyocyanin is a potent inducer of sialylomucins in vivo. We examined the ability of various 
purified PA components to induce changes in mucin glycosylation in chronic in vivo models of 
exposure. Recovered lung sections were stained using the high iron diamine-alcian blue (HID-
AB) stain to detect sialylomucins and sulfomucins. Although all bacterial components were able 
to induce at least a low level of sialylomucin staining compared to the PBS control, chronic 
administration of PCN resulted in the most dramatic increase in sialylomucins (Fig. 1).  For this 
reason, our study focused on the relationship between PCN and mucin sialylation. We observed 
no staining of sulfomucins in lung sections, despite a prominent presence in large colon control 
sections from the same animals (Fig. S1).   
Pyocyanin induces sialyl-Lewisx epitopes in bronchiolar epithelium in vivo. Previous studies 
have shown increased levels of sialic acid modifications to terminal mucin glycosylation chains 
in the form of sialylated Lewisx epitopes (Davril et al., 1999). Sialyl-Lewisx has been shown to be 
a preferential binding receptor for PA (Sharfman et al., 1999). We examined the effect of 
chronic PCN exposure on the levels of sialyl-Lewisx epitopes on the surface of the bronchial 
mucosa. Lung sections from mice chronically administered PCN were used for 
immunohistochemical (IHC) analysis with a primary antibody against sialyl-Lewisx. Chronic PCN 
administration significantly increases the sialyl-Lewisx epitopes in both large and small airways 
by 10 and 35-fold, respectively, when compared with baseline levels in control lungs exposed to 
PBS (Fig. 2). These results confirm that PCN induces an increase in the amount of sialyl-Lewisx 
present in bronchial mucosa in vivo. 
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Pyocyanin induces sialyl-Lewisx in cultured NCI-H292 airway epithelial cells. In order to more 
closely examine the mechanism of PCN’s effect on sialyl-Lewisx additions to mucin 
glycosylations, we tested the effect of PCN administration on the levels of sialyl-Lewisx in an in 
vitro cell culture model using the NCI-H292 airway epithelial carcinoma cells in western blotting 
analysis with a primary antibody against sialyl-Lewisx.  An increase in the level of the sialyl-
Lewisx signal was seen at 2.5 and 5.0 µg/mL concentrations after 24 hr (Fig. 3A).  Furthermore, 
PCN (5.0 µg/mL) induces a time-dependent increase in sialyl-Lewisx epitopes (Fig. 3B). To 
further confirm our findings, we performed immunofluorescence studies on NCI-H292 cells 
treated with PCN with the anti-sialyl-Lewisx antibody. In the PCN treated cells, 3.8-fold higher 
sialyl-Lewisx epitopes were seen, along with a change in cellular localization from perinuclear to 
diffuse cytoplasmic (Figs. 3C-D, S2). Taken together, these results confirmed the ability of PCN 
to induce sialyl-Lewisx in NCI-H292 cells in concentration and time dependent manners.  
Pyocyanin induces upregulation of C2/4GnT and ST3Gal-IV. Sialyl-Lewisx is synthesized through 
a stepwise process involving many enzymes (Delmotte et al., 2002). Previous work has shown 
that levels of sialyl-Lewisx biosynthesis enzymes C2/4GnT and ST3Gal-IV are upregulated in 
response to inflammation (Delmotte et al., 2001; Delmotte et al., 2002b; Groux-Degroote et al.,  
2008). We examined whether PCN could directly upregulate these enzymes by exposing H292 
cells to PCN in a time dependent manner. PCN significantly increased the amounts of both 
C2/4GnT (Fig. 4A) and ST3Gal-IV (Fig. 4B) by 4 and 3-fold, respectively. These results indicate 
that PCN is capable of upregulating the expression of enzymes crucial for the biosynthesis of 
sialyl-Lewisx.  
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PCN induces an increase in sialyl-Lewisx through the PI-PLC pathway. Most recently, we have 
shown that PCN induces the expression of MUC5B AND MUC5AC mucins through activation of 
EGFR (Hao et al., 2012). In contrast, EGFR has been shown to negatively regulate C2/4GnT and 
ST3Gal-IV (Beum et al., 2003; Ishibashi et al., 2005). Rather, these glycosyltransferases are 
induced through signaling in the phosphoinositol-specific phospholipase C (PI-PLC) pathway 
(Ishibashi et al., 2005).  To test whether PCN-induced upregulations in sialyl-Lewisx  and its 
biosynthetic enzymes C2/4GnT and ST3Gal-IV were also PI-PLC dependent, NCI-H292 cells were 
exposed to PCN either alone or in the presence of PI-PLC pathway inhibitor U-73122 in 
increasing concentrations.  Our results showed that PCN upregulated PLC-γ2 (Fig. S3), a 
pathway component of PI-PLC, and that cells treated with U-73122 had a dose-dependent 
decrease in PCN-mediated upregulation in sialyl-Lewisx, C2/4GnT, ST3Gal-IV (Fig. 5A-D).  These 
results indicate that upregulation of these components by PCN is occurring through signaling of 
the PI-PLC pathway.  
Pyocyanin increases binding affinity of P.aeruginosa to airway epithelial cells in vitro. Because 
sialyl-Lewisx has been shown to be a preferential binding receptor for PA (Scharfman et al., 
1999), and our results indicate a PCN-mediated increase in sialyl-Lewisx levels, we examined 
whether PA would be better able to bind to cells treated with PCN.  Our results showed a 50% 
increase in binding efficiency of PAO1 in the PCN-treated cell group (Fig. 6).  These results 
indicate that the modifications induced by PCN are able to facilitate the binding of PA in a more 
efficient manner. 
 
17 
 
DISCUSSION 
PCN is a redox-active phenazine toxin found to be excreted in levels up to 100 µM (27 
µg/mL) in PA-infected bronchiectatic airways (Wilson et al., 1988). In experimental mouse 
models, PCN has been found to be important for chronic lung infection, and also to cause 
goblet cell hyperplasia, airway fibrosis, and airspace destruction within the lung, pathological 
findings mirroring those found in a CF lung chronically infected with PA (Caldwell et al., 2009). 
Levels of sialyl-Lewisx, a binding receptor for PA, have also been found to be upregulated in 
mucins from patients with CF (Morelle et al., 2001; Shori et al., 2001), but historically have been 
primarily attributed to a condition of increased inflammation in the lung (Lamblin et al., 2001). 
Evidence suggesting the importance of bacterial infection in modulating levels of sialyl-Lewisx 
include observations of a correlation between severity of infection and increased sialyl-Lewisx 
expression (Davril et al., 1999; Morelle et al., 2001), as well as studies demonstrating an initial 
bacterial component required for inflammation in CF lungs (Berge, 2002; Dakin et al., 2002; 
Muhleback et al., 2002). We postulated that PA, or a factor thereof, may contribute to the 
initial stimulus in a pathway leading to increased sialyl-Lewisx. In this study, we show that 
chronic PCN administration increases the expression of sialylated mucins in mouse airways 
through a TNF--PI-PLC pathway. No sulfated mucins were detected in mouse airways, despite 
strong reactions on positive control slides of large colon tissue (Fig. S1). This is not surprising 
because mucin sulfation in cystic fibrosis has been shown to be directly linked to the primary 
genetic defect in the epithelium (Zhang et al., 1995), which is absent in our mouse model.  Our 
study also showed a causal link between chronic PCN administration in mouse airways and 
increased levels of sialyl-Lewisx (Fig. 2). This finding, as well as increased expression of C2/4GnT 
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and ST3Gal-IV, enzymes crucial for sialyl-Lewisx biosynthesis, was also seen in NCI-H292 cells 
cultured in vitro (Figs. 3 and 4). Collectively, these results demonstrate the ability of PCN to 
modulate sialyl-Lewisx synthesis.  
Previous studies have shown a significant increase in C2/4GnT, ST3Gal-IV and sialyl-
Lewisx in response to TNF-α, IL-6 and IL-8 in models of airway cell culture and culture of 
bronchial explants (Delmotte et al., 2002; Groux-Degroote et al., 2008; Ishibashi et al., 2005; 
Colomb et al., 2012). Upregulation of sialyl-Lewisx in response to TNF-α treatment was 
confirmed in our cell culture model (Fig. S4.)   In agreement, PCN has been shown to induce 
production and release of TNF-α, IL-6 and IL-8 from bronchial airway epithelial cells (Denning et 
al., 1998; Rada & Leto, 2011). Taken together, these results suggest PCN secreted from PA may 
increase sialyl-Lewisx by inducing TNF-α to produce observed effects in sialyl-Lewisx. Previous 
studies involving the effects of inflammatory cytokines on enzymes responsible for the 
synthesis of sialyl-Lewisx demonstrate, in addition to showing an increased expression in 
C2/4GnT and ST3Gal-IV, an upregulation in the expression of the α1-3 fucosyltransferase 
enzyme FucT-III/IV/VII (Delmotte et al., 2002; Ishibashi et al., 2005; Groux-Degroote et al., 
2008). Increased expression of FucT-III/IV/VII was not observed in response to PCN 
administration (data not shown). We hypothesize this may be due to higher sensitivity of FucT-
III/IV/VII than C2/4GnT and ST3Gal-IV to repression by the PCN-activated EGFR signaling 
pathway (Hao et al., 2012; Rada & Leto, 2011), which has been shown to be inhibitory to these 
glycosyltransferases (Ishibashi et al., 2005; Beum et al., 2003). It is possible that duality of 
action exerted by the TNF--PI-PLC and EGFR pathways seen as a result of PCN administration 
offer an environment in which the individual signaling pressures of multiple pathways are 
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summed to equal a different overall signaling stimulus than that of pure TNF-α, as in previous 
studies, and consequently yield a shifted response from downstream elements.  However, as 
PCN is present in appreciable quantities in the lungs of some CF patients (Wilson et al., 1988), 
the simultaneous upregulation of both signaling pathways may reflect more closely the 
stimulus environment of the airway during infection.  Further studies will be required to 
elucidate the interaction of PCN and FucT-III/IV/VII in the future.  
 Sialyl-Lewisx has been previously shown to be a preferential binding receptor for PA 
(Sharfman et al., 1999). Because PCN upregulates the amount of sialyl-Lewisx in mouse airways 
and H292 cells, this suggests it is able to alter the binding environment during chronic lung 
infection by PA. This suggestion proposes a PA-mediated binding environment more favorable 
for subsequent colonization after aggressive antibiotic therapy that would eradicate most PA 
cells, but would leave in the airway mucins more equipped to bind remaining PA or new 
bacteria that enter the airways.  Due to the reactivity of epithelium unique to the CF lung, it is 
also possible that these modified mucins may have continued production after the removal of a 
bacterial stimulus. In support of this idea, Muhleback et al described increased and prolonged 
inflammatory responses in CF lungs compared to non-CF lungs, which were also found in CF 
lungs devoid of bacterial infection, suggesting an inflammatory response in CF epithelium that 
is not only pronounced, but delayed in cessation after release of stimulation. In summary, PCN 
is able to modulate airway mucin glycosylation by the upregulation in levels of sialyl-Lewisx. The 
importance of this carbohydrate moiety as a binding receptor for PA underscores the 
importance in increasing knowledge of the effects of PCN on airway mucins. This current finding 
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adds further supporting evidence to the importance of PCN during PA-mediated chronic 
pulmonary infection in cystic fibrosis.  
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MATERIALS AND METHODS 
Chemicals and purified bacterial components. Chemically synthesized PCN was purchased 
from Sigma Aldrich (Sigma #R9532). Synthesized PCN is preferred to PCN purified from PA 
cultures to eliminate contaminants which may cause lung injury. PCN was resuspended in 
sterile water to a concentration of 0.25 µg/µL. PA LPS (Sigma) was instilled once daily 
intranasally at 2 g/mouse for 7 days. Alginate was purified from the mucoid PA strain FRD1 
and quantified as previously described (Hoffman et al., 2005), with some modifications.  Briefly, 
P. aeruginosa mucoid strain FRD1 was streaked on Pseudomonas isolation agar and grown at 
37C overnight. A sterile tip was used to inoculate 250mL of LB/ 1%glycerol media and grown at 
37C overnight, shaking at 250rpm. Cells from overnight growth were harvested by 
centrifugation at 10,000rpm on a Beckman JA-17 rotor. The resulting supernatant was 
transferred to a sterile container and heated at 80C for 30 minutes to inactivate enzymes. The 
alginate in the supernatant was precipitated by the addition of three volumes of ice-cold 
ethanol. Precipitated alginate, seen as a white clod, was harvested from the media with a 
sterile rod and was washed three times in sterile saline. The alginate was finally suspended in 
sterile saline and put to a shaker overnight to form a homogenous suspension.  Alginate was 
stored at 4C until use.  To quantify the concentration of alginate, a carbazole-borate assay was 
performed. Protocol from Knutson & Jeanes, 1968 was followed. Reagents: stock borate 
solution was made by dissolving 24.74g H3BO3 (boric acid) in 100mL 4M KOH (22.44g KOH in 
100mL H20) to give 4M BO3
3-. . H2SO4- borate reagent- 1.25mL stock borate solution was made 
to 50mL with concentrated H2SO4. Carbazole reagent: 0.1% solution prepared by dissolving 
carbazole in 100% EtOH.  Alginic acid standards: alginic acid Na salt (Sigma #180947) was used 
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as a standard. 35mg/mL was used as a starting concentration, dilutions of 1:1, 1:10 and 1:100 
were made for a standard curve. Assay procedure: 6mL of H2SO4-borate reagent was pipetted 
into each tube and equilibrated in an ice bath. Carefully, 0.7mL of test solution (sample or 
standard) was layered on top of the acid and allowed to equilibrate in an ice bath; the mixture 
was then vortexed for four seconds and equilibrated in an ice bath. Carbazole solution (0.2mL) 
was added and mixed, and the samples were heated in a 55C water bath for 20 min to allow 
color reaction to develop. 200ul of each sample or standard was transferred to a 96-well plate 
and absorbance was read at 450nm.  Flagella were purified from PA strain PAO1 as previously 
described (Campodonico et al., 2009). Briefly, 500ul of liquid overnight culture of P. aeruginosa 
strain PA01 was inoculated into 250mL of tryptic soy broth, and grown at 37C with shaking at 
200rpm. Cells were harvested at 10,000 RPM in a Beckman JA-14 rotor. The resulting cell pellet 
was resuspended in cold PBS. The resuspension was put into a blender and sheared for 35 
seconds. Resuspension was centrifuged at 13,000rpm in a Beckman JA-14 rotor. Resulting 
supernatant was further centrifuged at 40,000g for 3 hours in a Beckman H class ultracentrifuge 
with SW-28 rotor. Resulting pellets were resuspended in 10ul sterile PBS, and protein 
concentration was quantified by BCA assay. Samples were stored at -20C until use. U73122 was 
purchased from Sigma Aldrich (#U6756) and resuspended to a concentration of 0.9 mg/mL 
according to manufacturer’s instructions. TNF-α was purchased from R&D systems (#210-TA-
010) and resuspended to 100 µg/mL in sterile PBS with 0.1% BSA.  
Mouse exposure and lung tissue analyses. C57BL6 mice (6-week old, n = 10) Harlan Sprague 
Dawley) were housed in positively-ventilated microisolator cages with automatic recirculating 
water, located in a room with laminar, high efficiency particle accumulation-filtered air. The 
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animals received autoclaved food, water and bedding. PCN (25 µg), LPS (2 µg), alginate (90 µg), 
and flagella (2 µg) were intranasally inoculated into the lungs  of mice anaesthetized with 
isoflourane every 24 hours for 3 weeks or 7 days (LPS, alginate and flagella), respectively. 
Control mice were exposed to the same volume (50 µL) of sterile water. Time points were 
based on (for PCN and LPS) our previous studies demonstrating PCN and LPS-induced GCH in 
C57BL6 mice, where clear differences in lung pathology, cytokine and immune cells profiles can 
be detected between the treated and control mice (Caldwell et al., 2009; Hao et al., 2012, and 
unpublished observation), and in the case of alginate and flagella on previously published 
studies (Campodonico et al., 2009; Hoffman et al., 2005) as well as health status of mice. Lungs 
tissues were collected for histopathological analyses as we have previously described (Caldwell 
et al., 2009; Hao et al., 2012). Briefly, a cannula was inserted in the trachea, and the lung was 
instilled with 10% neutral buffered formalin at a constant pressure (25cm H20). The trachea was 
ligated, and the inflated lung was immersed in 10% neutral buffered formalin for 24 hours 
before embedding in paraffin wax. Paraffin embedded lung sections (4-8 m thickness) were 
stained with high-iron diamine-alcian blue (HID-AB) or periodic acid Schiff’s stain (PAS). For 
immunohistochemistry analyses, mouse lung sections were stained with primary antibody 
against sialyl-Lewisx (BD Pharmingen #551344); and visualized using the Vector M.O.M. 
immunodection kit (Vector Laboratories) according to the protocol supplied by the 
manufacturer. This study was carried out in strict accordance to the protocol approved by the 
Institutional Animal Care and Use Committee (IACUC) at the University of Illinois at Urbana-
Champaign. 
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Cell Culture. The human lung mucoepidermoid carcinoma cell line NCI-H292 was purchased 
from the American Type Culture Collection (ATCC) (Manassas). NCI-H292 cells were cultured in 
RPMI-1640 supplemented with 10% fetal bovine serum (Sigma) in 5% CO2.  Epithelial cells that 
reached 70% confluency were serum starved for 24hrs before exposure to PCN, TNF- or 
U73122. 
Sialyl-Lewisx, C2/4GnT, ST3Gal-IV and PLC-y2 analysis. NCI-H292 cells were stimulated with 
PCN (0.5, 2.5 and 5.0 µg/mL) for indicated time intervals (0, 0.25, 0.5, 1, 2, 4, 8, 12 and 24 hr). 
Total protein was extracted with M-PER Mammalian Protein Extraction Reagent (Thermo 
Scientific #78501). Protein concentration was determined with the Pierce BCA Protein Assay Kit 
(Thermo Scientific #23227). The same amount of protein from each treatment group was used 
in western blotting analysis. For inhibitor studies, NCI-H292 cells were serum starved for 24 hr 
and then exposed to the PI-PLC inhibitor U73122 at concentrations of 2.5 and 10 uM for 40 min 
before addition of PCN or the same volume of sterile PBS.  These cells were harvested after 24 
hr for western blotting analysis with antibodies against sialyl-Lewisx (BD Pharmingen #551344), 
C2/4GnT, ST3Gal-IV and PLC-y2 (Santa Cruz Biotechnology #sc-161625, #sc-134041, #sc-407, 
respectively). The immune complexes were visualized using the ECL Western Blotting Detection 
System (Amershan Biosciences) and Hyblot CL (Denville Scientific) autoradiography films. 
Immunofluorescence of sialyl-Lewisx. NCI-H292 cells were exposed to PCN (5 g/mL) for 24 hr. 
Immunofluorescence analysis was performed using a primary anti-sialyl-Lewisx antibody, 
followed by FITC-labeled secondary antibody (Alexa Flour® 488, Invitrogen). Slides were 
mounted using DAPI, and the subcellular localization of sialyl-Lewisx was observed using a 
confocal fluorescence microscope (Zeiss Axiovert 200M).   
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Image Analysis. Densitometry analysis of Western blots, total fluorescence levels of IFA images 
and threshold analysis of IHC staining area was accomplished using the ImageJ software from 
NIH (http://rsbweb.nih.gov/ij/).  Protocol for threshold analysis was as described (Vayrynen et 
al., 2012).  
PA binding assay. After reaching 70% confluency, NCI-H292 cells (~5x105 ) (n = 11 cell culture 
wells for each treatment) were serum starved for 24 hours before stimulation with 5 µg/mL 
PCN or equal volume of sterile PBS. After 16 hr, the cells were infected with ~ 5x105 PA strain 
PAO1 (MOI= 1:1). After 1 hr incubation, these wells were washed vigorously with 7 changes of 1 
ml sterile PBS. The epithelial cells were collected in 1 mL sterile PBS, serial diluted and plated 
onto Pseudomonas Isolation Agar for colony enumeration. 
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FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. PCN is a potent inducer of sialylomucins. Serial lung sections from mice (groups of 10) 
exposed to sterile H2O control or various purified PA components were stained using PAS to 
detect goblet cell hyperplasia and HID/ AB technique to detect sialylo- and sulfomucins.  
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Fig. 2. PCN induces the expression of sialyl-Lewisx epitopes in mouse airways. (A) IHC analyses of 
lung sections from mice exposed to PCN or same volume of sterile H2O were stained with an 
anti-sialyl-Lewisx antibody. Serial PCN-exposed sections were stained with PAS for the presence 
of goblet cell hyperplasia. (B) Quantification of percent sialyl-Lewisx stained area in control 
versus PCN-treated large and small airways.  
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Fig. 3.  PCN upregulates the expression of sialyl-Lewisx  in time and concentration-dependent 
manners. NCI-H292 cells were exposed to sterile H2O (control) or indicated concentrations of 
PCN or time intervals. Total proteins were harvested and the expression of sialyl-Lewisx was 
analyzed using specific antibody by Western blot (A and B). Membranes used in Western blot 
analysis were stripped and probed with antibody against β-actin for loading control.  
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Fig. 3. (Cont) (C) H292 cells were treated with 5ug/mL PCN for 24 hours and then used for 
immunofluorescence microscopy with anti-sialyl-Lewisx antibody. (D) Quantification of total 
fluorescence of control and PCN treated cells. Experiment was repeated 3 times with similar 
results. Analysis was accomplished by measuring total florescence in 10 representative high 
power fields from each treatment group in each individual experiment. *p < 0.05.  
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Fig. 4. PCN induces the expression of sialyl-Lewisx biosynthetic enzymes. NCI-H292 cells were 
exposed to 5 µg/mL PCN for the indicated time intervals. (A) The expression of C2/4GnT and 
ST3Gal-IV was analyzed by western blot. The membranes were stripped and probed with 
antibody against β-actin for loading controls. Experiments were repeated three times with 
similar results. Densitometry analysis of C2/4GnT (B) and ST3Gal-IV (C) from one of the 
representative western blots is shown.  
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Fig. 5. PCN upregulates sialyl-Lewisx through a phosphoinositol-specific phospholipase C (PI-
PLC) pathway. NCI-H292 cells were exposed to PI-PLC inhibitor U73122 (2.5 or 10 µM) for 40 
minutes before the addition of sterile H2O or PCN (5 µg/mL) for 24 hr. Total cell lysates were 
used in Western blot analysis using antibodies against sialyl-Lewisx, C2/4GnT or ST3Gal-IV (A). 
Membranes were stripped and probed with antibody against β-actin for loading control. 
Experiments were repeated three times with similar results. Densitometry data for sialyl-Lewisx 
(B), C2/4GnT (C) and ST3Gal-IV (D) from one representative western blot is shown.  
 
 
C2/4GnT 
β-actin 
ST3Gal-IV 
β-actin 
Sialyl-
Lewis X 
      PCN 
U73122  
β-actin 
270kDa 
      -               +               +                + 
      -               -                +              ++ 
A 
C 
B 
D 
32 
 
 
 
 
 
 
 
Fig. 6. Pyocyanin increases P. aeruginosa binding efficiency to NCI-H292 airway epithelial cells. 
PA strain PAO1 was added in a 1:1 ratio to wells (n = 11) of NCI-H292 cells treated with sterile 
H2O or PCN (5. µg/ml) for 24 hr. After 60 min, cells were washed, and scraped off and plated on 
Pseudomonas isolation agar. Data represents colony forming units recovered from each group. 
*p < 0.05.  
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Fig. S1. Section of large colon used as a positive control tissue for the high iron diamine-alcian 
blue (HID-AB) staining.  
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Fig. S2. Brightfield microscopy image of fixed NCI-H292 cells used for immunofluorescence 
assay to detect sialyl-Lewis
x
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Fig. S3. A) Western blot of total protein from NCI-H292 cells treated with indicated 
concentrations of PCN, and probed with an antibody against PLC-γ2. B) Densitometry analysis of 
A. *=p<0.05 
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Fig. S4. H292 cells were treated with 20ng/mL TNF-α and extracted total protein was used in 
Western blot analysis with antibody against sialyl-Lewisx. The same membrane was stripped 
and probed with antibody against β-actin for loading control. 
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